Background International differences in management/outcomes among patients with type 2
diabetes and heart failure (HF) are not well characterized. We sought to evaluate …

Importance Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor
(DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The …

Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and
mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of …

Aim The optimal strategy for diabetes control in patients with heart failure (HF) following
myocardial infarction (MI) remains unknown. Metformin, a guideline‐recommended therapy …

Aim To describe differences in patient characteristics and outcomes by ethnicity in patients
with diabetes mellitus (DM) and heart failure (HF) with reduced ejection fraction (HFrEF …

Aims Although diabetes mellitus (DM) is a common co‐morbidity in chronic heart failure (HF)
patients, European data on concurrent HF and DM treatment are lacking. Therefore, we …

OBJECTIVE Diabetes mellitus is associated with an increased risk of cardiovascular disease
(CVD) and death. Because the prevalence of diabetes is rising worldwide and chronic heart …

Diabetes and heart failure (HF) are both global epidemics with tremendous costs on society
with increased rates of HF hospitalizations and worsened prognosis when co-existing …

Background: Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM)
with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in …

Abstract Background Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
assessed the cardiovascular (CV) safety of sitagliptin versus placebo on CV outcomes in …